Previous 10 | Next 10 |
Live Event to be Held Thursday, August 31, at 7:30 pm Eastern Time Encinitas, California--(Newsfile Corp. - August 29, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) invites you to participate in a webinar highlighting the progress of molecular photoswitches in retinitis pigmentosa and the futur...
2023-08-23 10:28:02 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Nikola (NASDAQ: NKLA ) stock is a hot topic among traders on Wednesday after the electric vehicle (EV) company revealed the reselling of its shares. According to a filing ...
2023-08-23 10:10:20 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Mallinckrodt (NYSEMKT: MNK ) stock isn’t doing so hot on Wednesday after the pharmaceutical company gets ready for another bankruptcy filing. A press release from M...
2023-08-23 09:54:27 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Kiora Pharmaceuticals (NASDAQ: KPRX ) stock is getting a boost on Wednesday after the company revealed new patents in the U.S. and Europe. According to a press release f...
Encinitas, California--(Newsfile Corp. - August 23, 2023) - Kiora Pharmaceuticals, Inc . (NASDAQ: KPRX) ("Kiora" or the "Company") today announced it has been granted U.S. (Patent # 11,730,716) and European Patents covering local ocular delivery of the KIO-100 family of non-steroidal, anti-inf...
Encinitas, California--(Newsfile Corp. - August 22, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), a clinical-stage biotechnology company developing novel therapies for the treatment of ophthalmic diseases, today announced it has partnered with B2i Digital, Inc. to execute a comprehensive di...
Encinitas, California--(Newsfile Corp. - August 16, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) welcomes investors to watch the Company's online presentation from the H.C. Wainwright 3 rd Annual Ophthalmology Virtual Conference. As part of the talk, Kiora President & CEO Brian Strem, Ph.D...
2023-08-08 07:57:39 ET Kiora Pharmaceuticals press release ( NASDAQ: KPRX ): Q2 net loss was $2.6 million for the second quarter of 2023 compared to $2.4 million for the second quarter of 2022. This decrease was primarily due to lower personnel and facilities expenses offset b...
Positive Preliminary Data Reported in Q2 Demonstrated Clear Clinical Proof-of-Concept of KIO-301 in the Ongoing Phase 1 Study in Retinitis Pigmentosa Supporting Advancement to Planned Higher Doses with Full Topline Results Expected in Q4 2023 Data Supports Hypothesized Mechanism of Action of KIO...
Encinitas, California--(Newsfile Corp. - August 3, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), a clinical-stage ophthalmic pharmaceutical company developing novel therapeutics for patients with high unmet needs, and the Choroideremia Research Foundation (CRF), the largest organization in ...
News, Short Squeeze, Breakout and More Instantly...
Kiora Pharmaceuticals Inc. Company Name:
KPRX Stock Symbol:
NASDAQ Market:
Encinitas, California--(Newsfile Corp. - June 25, 2024) - Kiora Pharmaceuticals (NASDAQ: KPRX) has appointed Roger A. Goldberg, MD, MBA, a vitreoretinal surgeon at Bay Area Retina Associates (BARA) to its Scientific Advisory Board. As an advisor, Dr. Goldberg will contribute scientific insights a...
Phoenix, Arizona and New York, New York--(Newsfile Corp. - May 29, 2024) - Lytham Partners, a leading investor relations and corporate access firm, today announced the schedule for its Spring 2024 Investor Conference taking place virtually on May 30, 2024. More than 40 companies will be available...
Encinitas, California--(Newsfile Corp. - May 20, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (KPRX) ("Kiora" or the "Company"), will participate in two upcoming investor conferences that will be available to investors live with the replay available on-demand. On Wednesday May 22, at 3:00...